title: Inflammation in atherosclerosis: new opportunities for drug discovery.
abstract: Many lines of evidence indicate that inflammation is the ultimate cause of atherosclerosis; high cholesterol levels cause atherosclerosis through mechanism of inflammation. Drugs designed to address inflammatory aspects of atherosclerosis will likely be more effective than current therapies in treating and preventing coronary artery disease.
authors.affiliation: AtheroGenics, Inc., 8995 Westside Parkway, Alpharetta, Georgia 30004, USA. cmeng@atherogenics.com
authors.forename: Charles Q
authors.initials: CQ
authors.lastname: Meng
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D002097:C-Reactive Protein / Q000502:physiology; D015815:Cell Adhesion Molecules / Q000187:drug effects; D018925:Chemokines / Q000502:physiology; D002784:Cholesterol / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology
chemical_list: D015815:Cell Adhesion Molecules; D018925:Chemokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D002784:Cholesterol